News: GSS Genetic Signatures Expects Sales Of At Least A$21M For Half Year, page-17

Looking at current testing numbers and covid cases, one would think the next quarter will be huge for revenue. NSW and Victoria been pretty steady along, yet with UK and QLD testing numbers rising quite high and GSS signing up with a pathology lab in QLD, I’ll put my money on next quarter being a record breaker. Two to three quarters of good revenue ahead, should match up with FDA approval time wise for new testing kits so not burning money waiting. By then should have $40-45 million in the bank so highly unlikely there’ll ever be a need for a CR in the distant future which bodes well for shareholders. That’s always a big one for me when investing, low number of shares on offer.